Nurix Therapeutics (NRIX) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 131.2% versus a loss of 10.4%. Over five years, SUPN leads with a +36.0% price change compared with -21.2% for NRIX. Supernus Pharmaceuticals is the larger company by market cap ($2.51 billion vs $2.36 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | SUPN |
|---|---|---|
| Share price | $22.73 | $43.05 |
| Market cap | $2.36B | $2.51B |
| 1-day change | +0.58% | +0.51% |
| YTD return | +19.82% | -13.38% |
| 1-year return | +131.23% | -10.44% |
| 5-year return | -21.16% | +35.98% |
| Forward P/E | — | 9.65 |
| EPS (TTM) | $-3.46 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | — | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $28.23 | $59.68 |
| 52-week low | $9.00 | $40.51 |
| Distance from 52-week high | -19.48% | -27.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +49.27% | +43.44% |
| Average volume | 1.27M | 769.62K |
| Shares outstanding | 103.78M | 58.22M |
| Employees | 317 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed SUPN by 141.7 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
NRIX vs SUPN FAQ
Which is bigger, Nurix Therapeutics or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.51B compared with $2.36B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, NRIX or SUPN?
NRIX returned +131.23% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.